<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03944681</url>
  </required_header>
  <id_info>
    <org_study_id>KB01</org_study_id>
    <nct_id>NCT03944681</nct_id>
  </id_info>
  <brief_title>Gender Influence on Torsadogenic Actions of Droperidol.</brief_title>
  <official_title>Gender Influence on Torsadogenic Actions of Droperidol Used as Postoperative Nausea and Vomiting Prophylaxis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative nausea and vomiting (PONV) is a quite common complication affecting patients&#xD;
      undergoing general anesthesia. There are a few pharmacological agents of well known&#xD;
      effectiveness in reducing the risk of PONV. One of them is droperidol, which is a&#xD;
      butyrophenone derivant. It has been widely used for the prevention and treatment of PONV due&#xD;
      to its high effectiveness and low cost. Though, droperidol has a relevant side effect, that&#xD;
      is a repolarization prolongation. This can lead to life-threatening cardiac arrhythmias:&#xD;
      polymorphic ventricular tachycardia (torsades de pointes, TdP) that can degenerate into&#xD;
      ventricular fibrillation and cardiac arrest. This was a reason why in 2001 the FDA issued a&#xD;
      &quot;black box&quot; warning on droperidol. Ever since papers focused on this problem have described&#xD;
      the influence of small doses of droperidol on TdP genesis as weak. This could be explained by&#xD;
      the fact, that QT/QTc (corrected QT) interval prolongation, which represents prolonged&#xD;
      cardiac repolarization on ECG, is not the sole determinant of a drug's potential to cause&#xD;
      arrhythmia. Another electrocardiographical marker of torsadogenic action is increased&#xD;
      transmural dispersion of repolarization (TDR). TDR represents differences in the&#xD;
      repolarization between myocardial &quot;layers&quot; (like epicardium, endocardium, myocardium cells).&#xD;
      It is believed that the induction of QT/QTc lengthening must coexist with TDR increase at the&#xD;
      same time to promote torsadogenic changes.&#xD;
&#xD;
      It has been known, on the basis of research, that females have been more potent to&#xD;
      torsadogenic actions of pharmacological agents than males. That could be related to estrogen&#xD;
      influence on ECG parameters, which had been proven on animal model. It hasn't been&#xD;
      investigated, whether gender is an important factor when considering droperidol's&#xD;
      torsadogenic potential.&#xD;
&#xD;
      The aim of this study is to answer a hypothesis, that women are more potent to torsadogenic&#xD;
      actions of droperidol in comparison with men.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QT and corrected QT interval time</measure>
    <time_frame>Change from baseline QT and corrected QT interval time at 5,10,15 and 20 minutes after administration of 1.25 mg droperidol</time_frame>
    <description>measured in milliseconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time interval between T wave peak and T wave end</measure>
    <time_frame>Change from baseline T peak - T end time at 5,10,15 and 20 minutes after administration of 1.25 mg droperidol.</time_frame>
    <description>measured in milliseconds</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Arrhythmia, Droperidol</condition>
  <arm_group>
    <arm_group_label>Droperidol group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Droperidol (Xomolix, Kyowa Kirin) 1.25 mg i.v. bolus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droperidol Injectable Solution</intervention_name>
    <description>An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.</description>
    <arm_group_label>Droperidol group</arm_group_label>
    <other_name>electrocardiogram analysis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 45 years old&#xD;
&#xD;
          -  ASA (American Society of Anaesthesiologists) physical status 1 and 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lack of informed consent&#xD;
&#xD;
          -  ASA (American Society of Anaesthesiologists) physical status 3 and more&#xD;
&#xD;
          -  admittance of repolarisation affecting drugs like: antiarrhythmics (Williams group&#xD;
             I-IV), psychotropics, macrolides, antireflux drugs&#xD;
&#xD;
          -  ischaemic heart disease&#xD;
&#xD;
          -  cardiac failure NYHA (Hew York Heart Association) 1 and more&#xD;
&#xD;
          -  congenital or acquired heart defects&#xD;
&#xD;
          -  arrhythmias in anamnesis&#xD;
&#xD;
          -  hormonal contraception,&#xD;
&#xD;
          -  postmenopausal&#xD;
&#xD;
          -  neoplasms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Radoslaw Owczuk, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Gdansk</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karol Broniecki, MD</last_name>
    <phone>+48 58 726 02 87</phone>
    <email>k.broniecki@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radoslaw Owczuk, Prof.</last_name>
      <phone>(+48) 58 349 32 80</phone>
      <email>radoslaw.owczuk@gumed.edu.pl</email>
    </contact>
    <contact_backup>
      <last_name>Karol Broniecki, MD</last_name>
      <phone>(+48) 58 726 02 87</phone>
      <email>k.broniecki@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Gdansk</investigator_affiliation>
    <investigator_full_name>Radoslaw Owczuk</investigator_full_name>
    <investigator_title>Clinical Professor, Head of Department of Anaesthesiology and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>postoperative nausea and vomiting</keyword>
  <keyword>torsadogenic action</keyword>
  <keyword>transmural dispersion of repolarisation</keyword>
  <keyword>corrected QT interval</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Droperidol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

